Myriad Announces New GeneSight® Study Published in Personalized Medicine

Study based upon OptumInsight data showed More Than $6,200 in First Year Healthcare Costs Compared to Treatment-As-Usual for Patients with Depression SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight® combinatorial pharmacogenomic (CPGx) test on major commercial health plans was published in the journal Personalized Medicine.  The study concluded that “use of CPGx yielded reduced spending for a commercial health plan across the patient…

Read More

True Nature Holding Inc. Appoints Advertising and Digital Web Technology Executives to Advisory Board

ATLANTA, Sept. 26, 2018 (GLOBE NEWSWIRE) — True Nature Holding, Inc. (OTCQB:TNTY) (the “Company” or “True Nature”) announces the appointment of  Mr. Jim Crone and Mr. Craig Olivas to its Advisory Board. Both are seasoned executives with experience in corporate growth. Crone will support the team as an advisor on market analysis and digital advertising strategy and Olivas will advise on technical implementation and web presence. “We initiated our Advisory Board in 2016 to help us efficiently expand our subject matter expertise in core areas. These professionals provide us with…

Read More

Fibrocell to Present at Upcoming Industry and Investor Conferences

EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) — Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at these industry and investor conferences in October 2018: Cell & Gene Meeting on the Mesa on Wednesday, October 3rd at 3:00 p.m. PDT in La Jolla, CA Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9th at 7:30 a.m. EDT in New York City A live webcast of…

Read More

Globus Medical Sponsors NASS 2018, Hosts In-Booth Presentations on ExcelsiusGPS®

AUDUBON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will feature its ExcelsiusGPS® revolutionary robotic guidance and navigation system along with its latest advancements in expandable interbody technology at the North American Spine Society (NASS) Annual Meeting being held September 26-29, 2018 in Los Angeles, CA. Globus Medical’s participation at NASS includes two in-booth presentations from surgeons currently using ExcelsiusGPS® that highlight the versatility of robotic guidance and navigation in both minimally invasive and complex deformity procedures. In addition to the presentations,…

Read More

Myriad Announces Publication of Variant Reclassification Study in the Journal of the American Medical Association

Results Show 25 Percent of All Reported Variants of Uncertain Significance Were Reclassified over a 10-Year Period SALT LAKE CITY, Sept. 25, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that results from a landmark study of variant classifications following hereditary cancer genetic testing were published in the Journal of the American Medical Association (JAMA).  “This is the first large, robust study to quantify the prevalence of variant reclassification of hereditary cancer testing in a large commercial laboratory, underscoring Myriad’s commitment…

Read More

Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

EXTON, Pa., Sept. 25, 2018 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has awarded a $1.4 million clinical trial research grant for Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating, rare skin blistering disease with high mortality. “We are delighted with the FDA’s…

Read More

Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting

WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) — Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present four posters, including new analyses from the Phase 3 ACTIVExtend trial of abaloparatide injection, at the upcoming American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting, which will take place in Montreal. Radius Health will also present epidemiologic data on osteoporosis-related fractures from a population of managed care enrollees…

Read More

BioSig Technologies Retains Gilmartin Group for Investor Relations

Santa Monica, CA, Sept. 24, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it has retained Gilmartin Group for strategic investor relations and communication services.  “We are delighted to engage the team at Gilmartin Group as investor relations advisors. BioSig places a high priority on shareholder value and I am confident that Gilmartin’s extensive experience in capital markets, combined with their deep…

Read More

ProQR Announces Presentations at the OTS Annual Meeting

LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the Oligonucleotide Therapeutics Society (OTS) annual meeting to be held from September 30 – October 3, 2018 in Seattle, WA. Oral presentation on QR-110 clinical data in LCA10 David Rodman, MD, EVP of R&D of ProQR, will give a presentation on the recent clinical data from the QR-110 program for Leber’s…

Read More

Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration

Sunnyvale, Sept. 24, 2018 (GLOBE NEWSWIRE) — Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, reports the shipment of clinical instrumentation and quantification software to the United States Food and Drug Administration (FDA).  Arrayit uses the same instrumentation and software to test for allergy and food intolerance as well as pipeline indications for ovarian cancer and Parkinson’s Disease (PD).  Testing is performed in the company’s Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the California Department of Public Health (CDPH) and the Center for Medicare and Medicaid Services…

Read More